INTRODUCTION: Central retinal vein occlusion is a severe eye disease that impairs vision. Although there are numerous systemic conditions reported to be a contributor, its exact pathophysiology has not been resolved, yet. The purpose of this study is to study the role of common thrombophilic polymorphisms in CRVO patientsMETHODS: We recruited 33 CRVO (25-non-ischemic versus eight ischemic CRVO) patients versus 30 controls and investigated Factor V Leiden (G1691A), Prothrombin (Factor II) G202110A, MTHFR (C677T), MTHFR (A1298C) and PAI-1 5G/4G polymorphisms in their venous blood DNA also hypertension, diabetes mellitus, glaucoma, smoking, and history of thrombosis evaluatedRESULTS: We found that MTHFR C677T polymorphisms, either in heterozygous or homozygous form, might be a risk factor for CRVO and systemic thrombosis. No differences were detected between CRVO and control groups in terms of possessing diabetes mellitus (p= 0.058>0.05), hypertension (p=0.3>0.05), smoking (p=0.923>0.05), having glaucoma (p=0.06> 0.05) or usage of anticoagulant drugs (p= 0.4 > 0.05). In patient history, the statistically significant difference was found regarding possessing a thrombotic event in the medical history in CRVO group (p= 0.001 < 0.05, four patients) versus the control group. On the other hand, ischemic CRVO group had significantly higher diabetes mellitus (p= 0.002 < 0.05) and hypertension (p= 0.031 < 0.05) than non-ischemic CRVO group.DISCUSSION AND CONCLUSION: MTHFR C677T mutation is a risk factor for CRVO but not for Factor V Leiden (G1691A), Prothrombin (Factor II G202110A), MTHFR (A1298C) and PAI-1 5G/4G mutations specifically for CRVO and diabetes mellitus and hypertension is important for ischemic CRVO. Further studies with enlarged sample sizes should be carried out.